Rahma Sameh Shaheen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rahma Sameh Shaheen has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Saad Elsaeidy
Faculty of Medicine, Benha University, Benha, Egypt
4 shared publications - Rahma Abdelaziz Ismail
Faculty of Medicine Benha University Benha Egypt
3 shared publications - Reem Sayad
Faculty of Medicine, Assiut University, Assiut, Egypt
3 shared publications - Eslam Afifi
Benha University
2 shared publications - Esraa Y. Salama
Faculty of Medicine, Benha University, Benha, Egypt
2 shared publications - Mohamed Ibrahim Aranda
Faculty of Medicine Benha University Benha Egypt
2 shared publications
Latest Publications
- 24 February 2026
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 174 (2) , 579-598
Elinzanetant: Efficacy and safety in the management of vasomotor symptoms in postmenopausal women, a systematic review and meta‐analysis with grading of recommendations assessment, development, and evaluation assessment
Background: Menopause is frequently associated with different symptoms and signs, such as vasomotor symptoms (VMSs), which can affect women's quality of life. While hormonal therapy is considered the traditional and most used medication for controlling these VMSs associated with menopause, neurokinin (NK) receptor antagonists resemble a novel, promising generation of medications that provide fewer adverse events compared to hormonal therapy. Elinzanetant is the first drug that can act on both NK‐1 and 3 receptors by selectively antagonizing them. It has also been developed for the management of moderate‐to‐severe VMSs. Objectives: We aim to investigate the effectiveness and safety of elinzanetant compared to placebo in the management of moderate and severe VMSs that are associated with postmenopausal women. Method: We conducted a search of four databases (PubMed, Cochrane, Web of Science, and Scopus) using the following search strategy: ([Elinzanetant) OR [NT‐814] OR [BAY 3427080] OR (NK Receptor Antagonist]) AND ([Menopausal Symptoms] OR [Flashes Vasomotor Symptoms] OR (VMS)) with no search restrictions or filters applied. Selection Criteria: We included randomized controlled clinical trials (RCTs) comparing elinzanetant to placebo in post‐menopausal women suffering from frequent moderate‐to‐severe VMSs that reported both efficacy and safety outcomes. We used a uniform Google Sheet designed to collect data from our included RCTs. After data collection, we used Review Manager Software (RevMan) V.5.4.1. to perform all the analyses and plots using a risk ratio (RR) with a 95% confidence interval (CI) for dichotomous outcomes and mean difference (MD) with a 95% CI for continuous outcomes. We conducted risk of bias assessment using Risk of Bias Assessment tool‐2 (ROB2). Results: We included five RCTs in our review with 1699 participants. Our results reported that elinzanetant demonstrated a statistically significant difference in reducing both frequency and severity of VMSs at week 4 compared to placebo (MD = −2.75, 95% CI: [−3.83, −1.67], P < 0.00001; MD = −0.29, 95% CI: [−0.35, −0.22], P < 0.00001, respectively). These results were maintained at week 12 for both frequency (MD = −2.30, 95% CI: [−3.00, −1.59], P < 0.00001) and severity (MD = −0.35, 95% CI: [−0.43, −0.28], P < 0.00001). Compared to placebo, elinzanetant was associated with a higher incidence of treatment‐emergent adverse events (TEAEs) (RR = 1.12, 95% CI: [1.03, 1.22], P < 0.01), TEAEs causing permanent discontinuation of the study drug (RR = 2.18, 95% CI: [1.45, 3.28], P = 0.0002), drug‐related TEAEs (RR = 1.92, 95% CI: [1.53, 2.41], P < 0.00001), headache (RR = 2.19, 95% CI: [1.38, 3.49], P = 0.0009), somnolence (RR = 2.96, 95% CI: [1.42, 6.17], P = 0.004), and fatigue (RR = 3.39, 95% CI: [1.77, 6.49], P = 0.0002). However, no statistically significant difference was observed in the incidence of serious TEAEs (RR = 1.70, 95% CI: [0.82, 3.54], P = 0.15). Conclusion: Elinzanetant showed significant efficacy in reducing both the frequency and severity of VMSs associated with post‐menopausal women at different time points, while concurrently improving outcomes associated with women's quality of life. While elinzanetant was associated with a higher incidence of non‐serious adverse events such as headache, somnolence, and fatigue, which led to more treatment discontinuations, it did not increase the risk of serious adverse events compared to placebo, indicating an acceptable safety profile. Conclusively, our results indicate that elinzanetant represents a promising alternative for VMS management; however, it should not replace the clinical assessment of eligibility for hormone therapy. Further studies are required to confirm its long‐term safety and sustained effectiveness. PROSPERO Registration: Our study was registered on PROSPERO on September 20, 2024, with ID CRD42024593052.
- 24 February 2026
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 174 (2) , 579-598
Elinzanetant: Efficacy and safety in the management of vasomotor symptoms in postmenopausal women, a systematic review and meta‐analysis with grading of recommendations assessment, development, and evaluation assessment
Background: Menopause is frequently associated with different symptoms and signs, such as vasomotor symptoms (VMSs), which can affect women's quality of life. While hormonal therapy is considered the traditional and most used medication for controlling these VMSs associated with menopause, neurokinin (NK) receptor antagonists resemble a novel, promising generation of medications that provide fewer adverse events compared to hormonal therapy. Elinzanetant is the first drug that can act on both NK‐1 and 3 receptors by selectively antagonizing them. It has also been developed for the management of moderate‐to‐severe VMSs. Objectives: We aim to investigate the effectiveness and safety of elinzanetant compared to placebo in the management of moderate and severe VMSs that are associated with postmenopausal women. Method: We conducted a search of four databases (PubMed, Cochrane, Web of Science, and Scopus) using the following search strategy: ([Elinzanetant) OR [NT‐814] OR [BAY 3427080] OR (NK Receptor Antagonist]) AND ([Menopausal Symptoms] OR [Flashes Vasomotor Symptoms] OR (VMS)) with no search restrictions or filters applied. Selection Criteria: We included randomized controlled clinical trials (RCTs) comparing elinzanetant to placebo in post‐menopausal women suffering from frequent moderate‐to‐severe VMSs that reported both efficacy and safety outcomes. We used a uniform Google Sheet designed to collect data from our included RCTs. After data collection, we used Review Manager Software (RevMan) V.5.4.1. to perform all the analyses and plots using a risk ratio (RR) with a 95% confidence interval (CI) for dichotomous outcomes and mean difference (MD) with a 95% CI for continuous outcomes. We conducted risk of bias assessment using Risk of Bias Assessment tool‐2 (ROB2). Results: We included five RCTs in our review with 1699 participants. Our results reported that elinzanetant demonstrated a statistically significant difference in reducing both frequency and severity of VMSs at week 4 compared to placebo (MD = −2.75, 95% CI: [−3.83, −1.67], P < 0.00001; MD = −0.29, 95% CI: [−0.35, −0.22], P < 0.00001, respectively). These results were maintained at week 12 for both frequency (MD = −2.30, 95% CI: [−3.00, −1.59], P < 0.00001) and severity (MD = −0.35, 95% CI: [−0.43, −0.28], P < 0.00001). Compared to placebo, elinzanetant was associated with a higher incidence of treatment‐emergent adverse events (TEAEs) (RR = 1.12, 95% CI: [1.03, 1.22], P < 0.01), TEAEs causing permanent discontinuation of the study drug (RR = 2.18, 95% CI: [1.45, 3.28], P = 0.0002), drug‐related TEAEs (RR = 1.92, 95% CI: [1.53, 2.41], P < 0.00001), headache (RR = 2.19, 95% CI: [1.38, 3.49], P = 0.0009), somnolence (RR = 2.96, 95% CI: [1.42, 6.17], P = 0.004), and fatigue (RR = 3.39, 95% CI: [1.77, 6.49], P = 0.0002). However, no statistically significant difference was observed in the incidence of serious TEAEs (RR = 1.70, 95% CI: [0.82, 3.54], P = 0.15). Conclusion: Elinzanetant showed significant efficacy in reducing both the frequency and severity of VMSs associated with post‐menopausal women at different time points, while concurrently improving outcomes associated with women's quality of life. While elinzanetant was associated with a higher incidence of non‐serious adverse events such as headache, somnolence, and fatigue, which led to more treatment discontinuations, it did not increase the risk of serious adverse events compared to placebo, indicating an acceptable safety profile. Conclusively, our results indicate that elinzanetant represents a promising alternative for VMS management; however, it should not replace the clinical assessment of eligibility for hormone therapy. Further studies are required to confirm its long‐term safety and sustained effectiveness. PROSPERO Registration: Our study was registered on PROSPERO on September 20, 2024, with ID CRD42024593052.
- Open Access
- 11 December 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 1732-1753
Effect of triple versus dual antiplatelet therapy in patients undergoing percutaneous intervention: systematic review and meta-analysis with GRADE system
Introduction: To lower major adverse cardiac events following percutaneous coronary intervention (PCI), antiplatelet therapy should be continued. We evaluated triple antiplatelet therapy (TAT) versus standard dual treatment (DAT) in patients having percutaneous intervention for coronary artery disease. Methods: On 17 July 2023, we systematically searched PubMed, Scopus, and the Web of Science databases. This systematic review included studies that assessed the effect of TAT versus DAT after PCI. The level of evidence of the included trials was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation approach. Results: Twenty-seven studies were included in this systematic review and meta-analysis. The meta-analysis showed that TAT is associated with a significant reduction in major adverse cardiac events (MACEs) at 9- and 12-month follow-up periods (risk ratio [RR] = 0.39, 95% confidence interval [CI], 0.20–0.77; P = 0.006 and RR = 0.57, 95% CI, 0.45–0.71; P < 0.00001), and also showed a significant reduction in target lesion revascularization (RR = 0.33, 95% CI, 0.15–0.73; P = 0.006, and RR = 0.45, 95% CI, 0.28–0.73; P = 0.001), respectively. It also showed a significant reduction in target vessel revascularization during the 9-month follow-up period (RR = 0.62, 95% CI, 0.48–0.81; P = 0.0004). While dual therapy has an insignificant reduction in any-degree bleeding at 6 and 12-month follow-up periods (RR = 1.02, 95% CI, 0.54–1.94; P = 0.94 and (RR = 1.28, 95% CI, 0.92–1.77; P = 0.14), compared with triple therapy. The level of evidence for MACEs, target lesion revascularization (TLR), and any degree of bleeding is moderate, but it is low for TVR, any cause of death, cardiac death, and stent thrombosis. All of them are assessed with a 12-month follow-up duration. Conclusion: TAT appears to be more effective than DAT in reducing MACEs, TLR, and TVR in acute coronary syndrome patients after PCI. TAT is almost as safe as DAT in these patients because there is a statistically insignificant difference in most of the adverse effects between these two groups.
- 11 December 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 1732-1753
Open AccessEffect of triple versus dual antiplatelet therapy in patients undergoing percutaneous intervention: systematic review and meta-analysis with GRADE system
Introduction: To lower major adverse cardiac events following percutaneous coronary intervention (PCI), antiplatelet therapy should be continued. We evaluated triple antiplatelet therapy (TAT) versus standard dual treatment (DAT) in patients having percutaneous intervention for coronary artery disease. Methods: On 17 July 2023, we systematically searched PubMed, Scopus, and the Web of Science databases. This systematic review included studies that assessed the effect of TAT versus DAT after PCI. The level of evidence of the included trials was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation approach. Results: Twenty-seven studies were included in this systematic review and meta-analysis. The meta-analysis showed that TAT is associated with a significant reduction in major adverse cardiac events (MACEs) at 9- and 12-month follow-up periods (risk ratio [RR] = 0.39, 95% confidence interval [CI], 0.20–0.77; P = 0.006 and RR = 0.57, 95% CI, 0.45–0.71; P < 0.00001), and also showed a significant reduction in target lesion revascularization (RR = 0.33, 95% CI, 0.15–0.73; P = 0.006, and RR = 0.45, 95% CI, 0.28–0.73; P = 0.001), respectively. It also showed a significant reduction in target vessel revascularization during the 9-month follow-up period (RR = 0.62, 95% CI, 0.48–0.81; P = 0.0004). While dual therapy has an insignificant reduction in any-degree bleeding at 6 and 12-month follow-up periods (RR = 1.02, 95% CI, 0.54–1.94; P = 0.94 and (RR = 1.28, 95% CI, 0.92–1.77; P = 0.14), compared with triple therapy. The level of evidence for MACEs, target lesion revascularization (TLR), and any degree of bleeding is moderate, but it is low for TVR, any cause of death, cardiac death, and stent thrombosis. All of them are assessed with a 12-month follow-up duration. Conclusion: TAT appears to be more effective than DAT in reducing MACEs, TLR, and TVR in acute coronary syndrome patients after PCI. TAT is almost as safe as DAT in these patients because there is a statistically insignificant difference in most of the adverse effects between these two groups.
- 12 November 2025
- Published by Springer Nature in International Ophthalmology
- Vol. 45 (1) , 1-16
The comparative efficacy and safety of one-site versus two-site phacotrabeculectomy: an updated systematic review and meta-analysis
Purpose To compare the efficacy and safety of one-site versus two-site phacotrabeculectomy in the management of concurrent cataract and glaucoma through an updated systematic review and meta-analysis of randomized controlled trials. Methods Systematic searches were conducted across seven electronic databases through February 2025. Only randomized controlled trials comparing one-site versus two-site phacotrabeculectomy were included. Primary outcome was intraocular pressure (IOP) reduction. Secondary outcomes included anti-glaucoma medication (AGM) use, visual acuity, endothelial cell loss, and complications. Meta-regression analyzed the effects of mitomycin C (MMC) usage, age, and follow-up duration on outcomes. Results Sixteen randomized controlled trials (1087 eyes) were included. Both techniques achieved comparable IOP reduction at most timepoints. Although two-site surgery demonstrated a trend toward greater IOP reduction at select intervals (e.g., day one and 18 months), these differences were not statistically significant. AGM requirements were similar between groups at 12 months (mean difference: 0.05; 95% CI − 0.16, 0.27). Visual outcomes were comparable, though influenced by age (p = 0.004) and MMC use (p = 0.025). Endothelial cell loss was initially greater with two-site surgery but stabilized over time. Complication rates, including hyphema (OR: 0.99; 95% CI: 0.56, 1.76) and bleb-related complications (OR: 1.09; 95% CI 0.55, 2.16), were similar between groups. Conclusions One-site and two-site phacotrabeculectomy demonstrate comparable efficacy and safety profiles. While two-site surgery shows a trend toward greater IOP reduction, the differences are not clinically significant. Surgical approach should be individualized based on patient characteristics, surgeon experience, and specific surgical goals rather than assumed superiority of either technique.
- 12 November 2025
- Published by Springer Nature in International Ophthalmology
- Vol. 45 (1) , 1-16
The comparative efficacy and safety of one-site versus two-site phacotrabeculectomy: an updated systematic review and meta-analysis
Purpose To compare the efficacy and safety of one-site versus two-site phacotrabeculectomy in the management of concurrent cataract and glaucoma through an updated systematic review and meta-analysis of randomized controlled trials. Methods Systematic searches were conducted across seven electronic databases through February 2025. Only randomized controlled trials comparing one-site versus two-site phacotrabeculectomy were included. Primary outcome was intraocular pressure (IOP) reduction. Secondary outcomes included anti-glaucoma medication (AGM) use, visual acuity, endothelial cell loss, and complications. Meta-regression analyzed the effects of mitomycin C (MMC) usage, age, and follow-up duration on outcomes. Results Sixteen randomized controlled trials (1087 eyes) were included. Both techniques achieved comparable IOP reduction at most timepoints. Although two-site surgery demonstrated a trend toward greater IOP reduction at select intervals (e.g., day one and 18 months), these differences were not statistically significant. AGM requirements were similar between groups at 12 months (mean difference: 0.05; 95% CI − 0.16, 0.27). Visual outcomes were comparable, though influenced by age (p = 0.004) and MMC use (p = 0.025). Endothelial cell loss was initially greater with two-site surgery but stabilized over time. Complication rates, including hyphema (OR: 0.99; 95% CI: 0.56, 1.76) and bleb-related complications (OR: 1.09; 95% CI 0.55, 2.16), were similar between groups. Conclusions One-site and two-site phacotrabeculectomy demonstrate comparable efficacy and safety profiles. While two-site surgery shows a trend toward greater IOP reduction, the differences are not clinically significant. Surgical approach should be individualized based on patient characteristics, surgeon experience, and specific surgical goals rather than assumed superiority of either technique.
- Open Access
- 7 July 2025
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 312 (5) , 1383-1386
Hystrosalpingo-foam sonography with ExEm and lidocaine-based foam gel for detecting tubal occlusion: a diagnostic test accuracy systematic review and meta-analysis
- 7 July 2025
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 312 (5) , 1383-1386
Open AccessHystrosalpingo-foam sonography with ExEm and lidocaine-based foam gel for detecting tubal occlusion: a diagnostic test accuracy systematic review and meta-analysis
- Open Access
- 2 June 2025
- Published by Springer Nature in Middle East Fertility Society Journal
- Vol. 30 (1) , 1-24
Efficacy and safety of fezolinetant and its different doses in the treatment of vasomotor symptoms in menopausal women: a systematic review and meta-analysis
Introduction: Fezolinetant, an oral NK3R antagonist, selectively blocks NKB signaling, improving vasomotor symptoms by reducing KNDy neuron activity. Our review assesses fezolinetant’s efficacy and safety in treating VMSs in menopausal women. Methods: We conducted a systematic review and meta-analysis synthesizing randomized controlled trials, which were retrieved by systematically searching PubMed, Scopus, Web of Science, Cochrane, Embase, MEDLINE, Ovid full text, and CINAHL until May 2023. We used RevMan V. 5.4 to pool dichotomous data using risk ratio and continuous data using the mean difference with a 95% confidence interval. Results: We included eight studies from seven RCTs. Fezolinetant showed significant efficacy in reducing the frequency of vasomotor symptoms in menopausal women, with a mean difference reduction of 1.96 episodes per day (95% CI [− 2.48, − 1.45], P < 0.00001). Additionally, women in the fezolinetant group were more likely to acquire a reduction of at least 70% from baseline in VMS frequency (OR = 2.22, 95% CI [1.55, 3.18]: P < 0.0001). Fezolinetant also showed significant efficacy in reducing the VMS severity after 12 weeks (MD = − 0.18, 95% CI [− 0.26, − 0.10], P < 0.0001). Quality of life measures also favored fezolinetant, showing a significant reduction in MENQOL score by 0.32 points (95% CI [− 0.52, − 0.13], P = 0.0009). Importantly, fezolinetant exhibited a favorable safety profile, with no significant difference in liver test elevations compared to placebo after 12 weeks (OR = 1.00, 95% CI [0.68, 1.47], P = 0.99). It also exhibited no statistically significant difference in treatment-emergent adverse events after 12 weeks by different doses (30, 45, and 180 mg). Conclusion: Fezolinetant demonstrated significant efficacy in reducing VMS frequency and severity and improving quality of life. Safety outcomes revealed no significant differences in liver safety assessments or treatment-emergent adverse events compared to placebo. Trial registration: PROSPERO CRD42023484019.
- 2 June 2025
- Published by Springer Nature in Middle East Fertility Society Journal
- Vol. 30 (1) , 1-24
Open AccessEfficacy and safety of fezolinetant and its different doses in the treatment of vasomotor symptoms in menopausal women: a systematic review and meta-analysis
Introduction: Fezolinetant, an oral NK3R antagonist, selectively blocks NKB signaling, improving vasomotor symptoms by reducing KNDy neuron activity. Our review assesses fezolinetant’s efficacy and safety in treating VMSs in menopausal women. Methods: We conducted a systematic review and meta-analysis synthesizing randomized controlled trials, which were retrieved by systematically searching PubMed, Scopus, Web of Science, Cochrane, Embase, MEDLINE, Ovid full text, and CINAHL until May 2023. We used RevMan V. 5.4 to pool dichotomous data using risk ratio and continuous data using the mean difference with a 95% confidence interval. Results: We included eight studies from seven RCTs. Fezolinetant showed significant efficacy in reducing the frequency of vasomotor symptoms in menopausal women, with a mean difference reduction of 1.96 episodes per day (95% CI [− 2.48, − 1.45], P < 0.00001). Additionally, women in the fezolinetant group were more likely to acquire a reduction of at least 70% from baseline in VMS frequency (OR = 2.22, 95% CI [1.55, 3.18]: P < 0.0001). Fezolinetant also showed significant efficacy in reducing the VMS severity after 12 weeks (MD = − 0.18, 95% CI [− 0.26, − 0.10], P < 0.0001). Quality of life measures also favored fezolinetant, showing a significant reduction in MENQOL score by 0.32 points (95% CI [− 0.52, − 0.13], P = 0.0009). Importantly, fezolinetant exhibited a favorable safety profile, with no significant difference in liver test elevations compared to placebo after 12 weeks (OR = 1.00, 95% CI [0.68, 1.47], P = 0.99). It also exhibited no statistically significant difference in treatment-emergent adverse events after 12 weeks by different doses (30, 45, and 180 mg). Conclusion: Fezolinetant demonstrated significant efficacy in reducing VMS frequency and severity and improving quality of life. Safety outcomes revealed no significant differences in liver safety assessments or treatment-emergent adverse events compared to placebo. Trial registration: PROSPERO CRD42023484019.
- 26 May 2025
- Published by Springer Nature in Neurosurgical Review
- Vol. 48 (1) , 1-10
Anterior vs. posterior approach for spinal accessory nerve transfer to suprascapular nerve in brachial plexus injury: a systematic review and meta-analysis of comparative studies
Spinal accessory nerve (SAN) to suprascapular nerve (SSN) transfer is an effective surgical option for traumatic brachial plexus injuries (BPIs) when nerve grafting is not applicable. It is performed via two approaches: anterior and posterior. Despite the theoretical advantages of the posterior approach, clinical trials have yielded variable outcomes. This study aimed to compare the outcomes of anterior and posterior approaches for SAN to SSN transfer in restoring the Range of motion (ROM) and strength of shoulder abduction and external rotation in BPIs. We searched PubMed, Embase, Cochrane Library, Scopus, and Web of Science to identify studies comparing anterior and posterior approaches for SAN to SSN transfer. Quality assessment was performed using the Cochrane RoB2 tool and Newcastle-Ottawa Scale. via RevMan 5.4, meta-analyses were conducted. We identified eight comparative studies with 311 patients (n = 140 for posterior transfer, n = 171 for anterior transfer). Both approaches showed comparable outcomes with statistically significant advantages to the posterior approach by a modest but meaningful difference in shoulder abduction ROM (MD: 8.98°, 95% CI: 1.19 to 16.78, P = 0.02, I² = 0%) and in the Modified Medical Research Council (MRC), The posterior approach was associated with 4.78 times higher odds of achieving a grade ≥ M3 on the MRC scale (OR: 4.78, 95% CI: 1.43 to 15.96, P = 0.01, I² = 0%). We suggest that when functional gains are a priority, surgeons consider the posterior approach while still accounting for patient/surgeon specific factors and injury details.
- 26 May 2025
- Published by Springer Nature in Neurosurgical Review
- Vol. 48 (1) , 1-10
Anterior vs. posterior approach for spinal accessory nerve transfer to suprascapular nerve in brachial plexus injury: a systematic review and meta-analysis of comparative studies
Spinal accessory nerve (SAN) to suprascapular nerve (SSN) transfer is an effective surgical option for traumatic brachial plexus injuries (BPIs) when nerve grafting is not applicable. It is performed via two approaches: anterior and posterior. Despite the theoretical advantages of the posterior approach, clinical trials have yielded variable outcomes. This study aimed to compare the outcomes of anterior and posterior approaches for SAN to SSN transfer in restoring the Range of motion (ROM) and strength of shoulder abduction and external rotation in BPIs. We searched PubMed, Embase, Cochrane Library, Scopus, and Web of Science to identify studies comparing anterior and posterior approaches for SAN to SSN transfer. Quality assessment was performed using the Cochrane RoB2 tool and Newcastle-Ottawa Scale. via RevMan 5.4, meta-analyses were conducted. We identified eight comparative studies with 311 patients (n = 140 for posterior transfer, n = 171 for anterior transfer). Both approaches showed comparable outcomes with statistically significant advantages to the posterior approach by a modest but meaningful difference in shoulder abduction ROM (MD: 8.98°, 95% CI: 1.19 to 16.78, P = 0.02, I² = 0%) and in the Modified Medical Research Council (MRC), The posterior approach was associated with 4.78 times higher odds of achieving a grade ≥ M3 on the MRC scale (OR: 4.78, 95% CI: 1.43 to 15.96, P = 0.01, I² = 0%). We suggest that when functional gains are a priority, surgeons consider the posterior approach while still accounting for patient/surgeon specific factors and injury details.
- Open Access
- 25 April 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-10
Prevalence and sociodemographic determinants of anemia among ever-married women of reproductive age in Jordan: insights from the 2023 Jordan population and family health survey
Background: Anemia, characterized by low haemoglobin levels, remains a critical public health issue, particularly among women of reproductive age. Despite global advancements in addressing anemia, it continues to be a widespread concern in Jordan. This study aims to examine the prevalence of anemia and the sociodemographic factors associated with it among ever-married women aged 15–49 in Jordan, utilizing data from the 2023 Jordan Population and Family Health Survey (JPFHS). Methods: This is a secondary analysis was conducted using data from the 2023 JPFHS. The survey employed a two-stage stratified cluster sampling method to collect comprehensive information on haemoglobin levels, sociodemographic characteristics, and various health-related factors. Anemia was classified into mild, moderate, and severe categories based on WHO guidelines, using hemoglobin levels obtained from capillary blood samples analyzed with portable HemoCue photometers. Multivariate logistic regression analysis was then performed to identify the independent predictors of anemia. Results: Among the 6,249 participants, the prevalence of anemia was 35.33%, with 1,089 cases of mild anemia, 1,022 moderate cases, and 96 severe cases. The highest incidence of severe and mild anemia was observed in the 45–49 age group (41.1% and 20.2%, respectively). Moderate anemia was most prevalent among women aged 35–39 (21.5%), while the highest proportion of non-anemic participants was found in the 30–34 age group (19.7%). Multivariable analysis showed that women living in northern regions had higher odds of anemia (P < 0.0001). Conversely, overweight (P = 0.03), obesity (P = 0.04), and daily smoking (P = 0.002) were associated with lower odds of anemia. Conclusion: Anemia remains a moderate yet concerning public health issue in Jordan, particularly among underweight women and those in northern regions. The findings emphasize the need for targeted nutritional interventions and region-specific healthcare strategies to address anemia risk. Public health programs should focus on improving dietary intake, especially among underweight women, to mitigate anemia and enhance overall women’s health outcomes.
- 25 April 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-10
Open AccessPrevalence and sociodemographic determinants of anemia among ever-married women of reproductive age in Jordan: insights from the 2023 Jordan population and family health survey
Background: Anemia, characterized by low haemoglobin levels, remains a critical public health issue, particularly among women of reproductive age. Despite global advancements in addressing anemia, it continues to be a widespread concern in Jordan. This study aims to examine the prevalence of anemia and the sociodemographic factors associated with it among ever-married women aged 15–49 in Jordan, utilizing data from the 2023 Jordan Population and Family Health Survey (JPFHS). Methods: This is a secondary analysis was conducted using data from the 2023 JPFHS. The survey employed a two-stage stratified cluster sampling method to collect comprehensive information on haemoglobin levels, sociodemographic characteristics, and various health-related factors. Anemia was classified into mild, moderate, and severe categories based on WHO guidelines, using hemoglobin levels obtained from capillary blood samples analyzed with portable HemoCue photometers. Multivariate logistic regression analysis was then performed to identify the independent predictors of anemia. Results: Among the 6,249 participants, the prevalence of anemia was 35.33%, with 1,089 cases of mild anemia, 1,022 moderate cases, and 96 severe cases. The highest incidence of severe and mild anemia was observed in the 45–49 age group (41.1% and 20.2%, respectively). Moderate anemia was most prevalent among women aged 35–39 (21.5%), while the highest proportion of non-anemic participants was found in the 30–34 age group (19.7%). Multivariable analysis showed that women living in northern regions had higher odds of anemia (P < 0.0001). Conversely, overweight (P = 0.03), obesity (P = 0.04), and daily smoking (P = 0.002) were associated with lower odds of anemia. Conclusion: Anemia remains a moderate yet concerning public health issue in Jordan, particularly among underweight women and those in northern regions. The findings emphasize the need for targeted nutritional interventions and region-specific healthcare strategies to address anemia risk. Public health programs should focus on improving dietary intake, especially among underweight women, to mitigate anemia and enhance overall women’s health outcomes.
- Open Access
- 25 July 2024
- Published by Springer Nature in BMC Women's Health
- Vol. 24 (1) , 1-11
Efficacy and safety of 12-hour versus 24-hour magnesium sulfate in management of patients with pre-eclampsia and eclampsia: a systematic review and meta-analysis
Introduction: Magnesium sulfate is the most utilized anticonvulsant for treating patients with eclampsia and pre-eclampsia. The purpose of this study is to determine whether the 12-h regimen of magnesium sulfate outweighs the 24-h regimen in both efficacy and safety in the management of patients with mild or severe pre-eclampsia and eclampsia. Methods: We searched six electronic databases: PubMed, Scopus, Web of Science, Cochrane Library, Ovid, and Google Scholar. This search was conducted to yield any studies that were published until 15 January 2023. We did the statistical analysis plan by Review Manager Software version 5.4. Results: We included 13 randomized control trials with 2813 patients in this systematic review. Our meta-analysis revealed that there were no statistically significant differences between the 12-h regimen of the magnesium sulfate group and the 24-h regimen of the magnesium sulfate group in our outcome of interest: occurrence of seizure (RD: -0.00, 95% CI [-0.01, 0.00], P = 0.56), diminished deep tendon reflexes (RD: -0.00, 95% CI [-0.01, 0.01], P = 0.80), respiratory depression (RD: -0.00, 95% CI [-0.02, 0.01], P = 0.57), and pulmonary edema (RD: -0.00, 95% CI [-0.01, 0.01], P = 0.85). Conclusion: Our study showed no statistically significant difference in effectiveness and toxicity risk between the 12-h and 24-h regimens.
- 25 July 2024
- Published by Springer Nature in BMC Women's Health
- Vol. 24 (1) , 1-11
Open AccessEfficacy and safety of 12-hour versus 24-hour magnesium sulfate in management of patients with pre-eclampsia and eclampsia: a systematic review and meta-analysis
Introduction: Magnesium sulfate is the most utilized anticonvulsant for treating patients with eclampsia and pre-eclampsia. The purpose of this study is to determine whether the 12-h regimen of magnesium sulfate outweighs the 24-h regimen in both efficacy and safety in the management of patients with mild or severe pre-eclampsia and eclampsia. Methods: We searched six electronic databases: PubMed, Scopus, Web of Science, Cochrane Library, Ovid, and Google Scholar. This search was conducted to yield any studies that were published until 15 January 2023. We did the statistical analysis plan by Review Manager Software version 5.4. Results: We included 13 randomized control trials with 2813 patients in this systematic review. Our meta-analysis revealed that there were no statistically significant differences between the 12-h regimen of the magnesium sulfate group and the 24-h regimen of the magnesium sulfate group in our outcome of interest: occurrence of seizure (RD: -0.00, 95% CI [-0.01, 0.00], P = 0.56), diminished deep tendon reflexes (RD: -0.00, 95% CI [-0.01, 0.01], P = 0.80), respiratory depression (RD: -0.00, 95% CI [-0.02, 0.01], P = 0.57), and pulmonary edema (RD: -0.00, 95% CI [-0.01, 0.01], P = 0.85). Conclusion: Our study showed no statistically significant difference in effectiveness and toxicity risk between the 12-h and 24-h regimens.
- 2 April 2024
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 25 (5-6) , 425-436
Artificial intelligence for screening and diagnosis of amyotrophic lateral sclerosis: a systematic review and meta-analysis
1. Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a rare neurodegenerative disease affecting both upper and lower motor neurons (1). It leads to a progressive loss of m...
- 2 April 2024
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 25 (5-6) , 425-436
Artificial intelligence for screening and diagnosis of amyotrophic lateral sclerosis: a systematic review and meta-analysis
1. Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a rare neurodegenerative disease affecting both upper and lower motor neurons (1). It leads to a progressive loss of m...